fulgent
genetics
announces
partnership
ohio
department
rehabilitation
correction
testing
temple
city
globe
newswire
fulgent
genetics
nasdaq
flgt
fulgent
genetics
company
technology
company
providing
comprehensive
testing
solutions
scalable
technology
platform
today
announced
ohio
department
rehabilitation
correction
odrc
selected
fulgent
genetics
testing
needs
ohio
department
rehabilitation
correction
leverage
fulgent
testing
capabilities
enterprise
platform
test
approximately
employees
routine
basis
partnership
encompasses
testing
locations
across
state
leverage
fulgent
enterprise
platform
fulgent
platform
enable
odrc
streamline
testing
process
either
giving
employee
qr
code
using
employer
id
linked
individual
sample
via
barcode
scan
supervision
returned
fulgent
lab
processing
reporting
employees
receive
results
within
hours
sample
receipt
look
forward
aiding
ohio
department
rehabilitation
correction
effort
protect
employees
curb
spread
across
facilities
commented
brandon
perthuis
chief
commercial
officer
fulgent
genetics
enterprise
platform
offering
enables
odrc
test
employees
extremely
efficient
manner
process
takes
approximately
one
minute
per
person
offering
provides
flexible
comprehensive
testing
solution
odrc
utilizes
testing
capabilities
fulgent
continues
raise
bar
offering
testing
solutions
meet
needs
large
organizations
municipalities
highly
efficient
accurate
fulgent
genetics
fulgent
genetics
proprietary
technology
platform
created
broad
flexible
test
menu
ability
continually
expand
improve
proprietary
genetic
reference
library
maintaining
accessible
pricing
high
accuracy
competitive
turnaround
times
combining
next
generation
sequencing
ngs
technology
platform
company
performs
sequencing
deletion
duplication
analysis
array
panels
tailored
meet
specific
customer
needs
company
launched
first
product
picture
genetics
new
line
screening
tests
combines
company
advanced
ngs
solutions
actionable
results
genetic
counseling
options
individuals
since
march
company
commercially
launched
several
tests
detection
virus
causes
novel
coronavirus
including
ngs
reverse
transcription
polymerase
chain
reaction
based
tests
company
received
emergency
use
authorization
eua
food
drug
administration
fda
tests
detection
using
upper
respiratory
specimens
nasal
nasopharyngeal
oropharyngeal
swabs
testing
service
picture
genetics
cornerstone
company
business
ability
provide
expansive
options
flexibility
clients
unique
testing
needs
comprehensive
technology
offering
including
cloud
computing
pipeline
services
record
management
web
portal
services
clinical
workflow
sequencing
service
automated
lab
services
picture
genetics
picture
genetics
platform
launched
fulgent
genetics
offers
consumers
direct
access
advanced
genetic
testing
analytics
capabilities
ease
comfort
home
affordable
price
point
picture
genetics
platform
provides
holistic
approach
genetic
screening
including
oversight
independent
physicians
well
genetic
counseling
options
complement
fulgent
genetics
comprehensive
genetic
testing
analysis
picture
genetics
platform
currently
offers
multiple
tests
providing
medically
actionable
results
professional
medical
one
easy
process
visit
information
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
examples
statements
press
release
include
statements
among
things
management
beliefs
judgments
estimates
regarding
fulgent
testing
solutions
including
technology
platforms
testing
solution
company
identification
evaluation
opportunities
ability
capitalize
opportunities
grow
business
expected
lab
capacity
results
turnaround
times
statements
statements
historical
facts
relate
future
events
circumstances
company
future
performance
based
management
current
assumptions
expectations
beliefs
concerning
future
developments
potential
effect
company
business
statements
subject
number
risks
uncertainties
may
cause
events
circumstances
described
press
release
occur
actual
results
differ
materially
adversely
described
implied
statements
risks
uncertainties
include
among
others
ongoing
impacts
pandemic
including
preventive
public
health
measures
may
continue
impact
demand
tests
pandemic
effects
global
supply
chain
market
potential
rate
degree
market
adoption
company
tests
including
tests
genetic
testing
generally
company
ability
capture
sizable
share
developing
market
genetic
testing
compete
successfully
markets
including
ability
continue
develop
new
tests
attractive
various
customer
markets
ability
maintain
turnaround
times
otherwise
keep
pace
rapidly
changing
technology
company
ability
maintain
low
internal
costs
business
model
particularly
company
makes
investments
across
business
company
ability
maintain
acceptable
margin
sales
tests
particularly
light
increasing
competitive
pressures
factors
may
continue
reduce
company
sale
prices
margins
tests
risks
related
volatility
company
results
fluctuate
significantly
period
period
risks
associated
composition
company
customer
base
fluctuate
period
period
comprised
small
number
customers
account
significant
portion
company
revenue
company
ability
grow
diversify
customer
base
increase
demand
existing
new
customers
company
investments
infrastructure
including
sales
organization
operational
capabilities
extent
investments
impact
company
business
performance
enable
manage
growth
may
experience
future
periods
company
level
success
obtaining
coverage
adequate
reimbursement
collectability
levels
payors
tests
company
level
success
establishing
obtaining
intended
benefits
partnerships
joint
ventures
relationships
company
compliance
various
evolving
complex
laws
regulations
applicable
business
industry
risks
associated
company
international
operations
company
ability
protect
proprietary
technology
platform
general
industry
economic
political
market
conditions
result
risks
uncertainties
statements
relied
viewed
predictions
future
events
statements
made
press
release
speak
date
press
release
company
assumes
obligation
update
publicly
statements
reflect
actual
results
changes
expectations
except
otherwise
required
law
company
reports
filed
securities
exchange
commission
sec
including
annual
report
form
year
ended
december
filed
sec
march
reports
files
time
time
including
subsequently
filed
quarterly
current
reports
made
available
company
website
upon
filing
sec
reports
contain
information
company
business
risks
affecting
business
investor
relations
contact
blueshirt
group
nicole
borsje
nborsje
media
contact
blueshirt
group
jeff
fox
jeff
